UPFRONT SURGERY AS FIRST-LINE TREATMENT IN PATHOLOGICAL N2 NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Bertolaccini, L. [1 ]
Prisciandaro, E. [1 ]
Sedda, G. [1 ]
Girelli, L. [1 ]
Ieo, L. Spaggiari [1 ]
机构：
[1] European Inst Oncol, Thorac Surg, Milan, Italy
来源：
CHEST | 2022年 / 161卷 / 06期
关键词：
lung cancer;
D O I：
10.1016/j.chest.2021.12.345
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：315A / 315A
页数：1
相关论文
共 50 条
  • [31] Prognostic Factors in Patients with Resected Pathological N2 Non-Small Cell Lung Cancer
    Goto, T.
    Nakamura, M.
    Shimizu, Y.
    Sato, S.
    Koike, T.
    Tsuchida, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S879 - S879
  • [32] Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?
    Dempke, Wolfram C. M.
    Fenchel, Klaus
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (05) : 538 - 542
  • [33] The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
    Spagnuolo, Alessia
    Gridelli, Cesare
    CANCERS, 2023, 15 (08)
  • [34] Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer
    Puneet Saxena
    Pawan Kumar Singh
    Prabhat Singh Malik
    Navneet Singh
    Current Treatment Options in Oncology, 2020, 21
  • [35] First-Line Treatment in eGFR Mutant non-Small Cell Lung Cancer: is There a Best Option?
    Bulbul, Ajaz
    Husain, Hatim
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [36] Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Fleeman, N.
    Bagust, A.
    McLeod, C.
    Greenhalgh, J.
    Boland, A.
    Dundar, Y.
    Dickson, R.
    Smith, C. Tudur
    Davis, H.
    Green, J.
    Pearson, M.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 47 - 53
  • [37] Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer
    Saxena, Puneet
    Singh, Pawan Kumar
    Malik, Prabhat Singh
    Singh, Navneet
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (08)
  • [38] First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer
    Lange, T
    Müller-Tidow, C
    Serve, H
    Hoffknecht, P
    Berdel, WE
    Thomas, M
    ONCOLOGY REPORTS, 2005, 14 (06) : 1539 - 1542
  • [39] Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Brown, T.
    Boland, A.
    Bagust, A.
    Oyee, J.
    Hockenhull, J.
    Dundar, Y.
    Dickson, R.
    Ramani, V. S.
    Proudlove, C.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 71 - 79
  • [40] Pembrolizumab in Combination with Chemotherapy as First-Line Treatment of Advanced Non-Small Cell Lung Cancer
    Jahan, N.
    Swarup, S.
    Sultan, A.
    Naing, T.
    Mogollon-Duffo, F.
    Ball, S.
    Tun, A.
    Htut, T.
    Dash, A.
    D'Cunha, N.
    Hardwicke, F.
    Awasthi, S.
    Tijani, L.
    Thein, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S917 - S918
12345